JG
AXSM icon

Joel Greenblatt’s Axsome Therapeutics AXSM Stock Holding History

Joel Greenblatt’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$240K Buy
+980
New +$213K ﹤0.01% 1701
2020
Q1 		– Sell
-2,495
Closed -$258K – 1076
2019
Q4 		$258K Buy
+2,495
New +$101K ﹤0.01% 977
2019
Q3 		– Sell
-11,158
Closed -$287K – 1088
2019
Q2 		$287K Buy
+11,158
New +$224K ﹤0.01% 967

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Joel Greenblatt's AXSM Position: Q2 2026 in Review

Joel Greenblatt opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 980 shares worth $240K. The stake represents ﹤0.01% of the portfolio and ranks #1701 among its holdings. This is a return to the name: Joel Greenblatt previously reported a position in AXSM as recently as Q4 2019.

Joel Greenblatt first reported a position in AXSM in Q2 2019 and has held it in 3 quarters since. The position peaked at $287K in Q2 2019. 502 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Joel Greenblatt held 980 shares of Axsome Therapeutics worth $240K as of Q2 2026.
  • Axsome Therapeutics was a new Joel Greenblatt position in Q2 2026.
  • Axsome Therapeutics made up ﹤0.01% of Joel Greenblatt's portfolio in Q2 2026, its #1701 holding.
  • Joel Greenblatt first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 3 quarters since.
  • Joel Greenblatt's Axsome Therapeutics position peaked at $287K in Q2 2019.
  • 502 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.